On the Record · Keenova Therapeutics

Keenova Therapeutics acquisitions, on the record

The businesses Keenova Therapeutics bought and sold, as its annual reports describe them, with the cash it reported paying for acquisitions each year and every deal filing since 2016.

Deals its annual reports describe

Business	Deal	When	Value
Amitiza Word for word“Prior to our acquisition of Amitiza in February 2018, the previous owner had entered into agreements to license certain rights to Amitiza to third parties in exchange for royalties on net sales of the product.” 10-K for 2023	acquisition	February 2018	—
Acthar Gel Word for word“Certain press reports and other commentary have criticized the increases in the price of Acthar Gel over time, including related to the period prior to our acquisition of the product.” 10-K for 2023	acquisition	—	—
Therakos Word for word“mnk:TherakosDivestitureMember 2023-12-30 2024-12-27” 10-K for 2024	divestiture	—	—
Par Health Word for word“On November 10, 2025 (the “Redemption Date”), we completed the Separation of our generic pharmaceuticals and sterile injectables businesses into an independent, private company named Par Health.” 10-K for 2025	divestiture	November 10, 2025	—
Endo Word for word“On July 31, 2025, we completed the Business Combination with Endo, whereby we acquired all of the issued and outstanding shares of common stock of Endo in exchange for a combination of cash and our ordinary shares in accordance with the Transaction Agreement (as amended on April 23, 2025) (“Transaction Agreement”) entered into on March 13, 2025, among us, Endo, and our wholly owned subsidiary, Salvare Merger Sub LLC (“Merger Sub”).” 10-K for 2025	acquisition	July 31, 2025	—
Therakos business Word for word“On November 29, 2024, we completed the sale of our Therakos business to affiliates of CVC Capital Partners IX for total cash consideration of $887.6 million, which amount was net of preliminary purchase price adjustments, including an adjustment based on estimated net working capital at close, and we recorded a gain on sale of $754.4 million.” 10-K for 2025	divestiture	November 29, 2024	$887.6 million

As filedReported in the company's financial data (XBRL), each linked to its filing
Fiscal year ended	Cash paid for acquisitions (net of cash acquired)	Goodwill from acquisitions
2016-09-30	$245.4 million	—
2017-12-29	$76.3 million	—
2018-12-28	$699.9 million	—
2019-12-27	$0	—
2020-12-25	$0	—
2025-12-31	—	$31.8 million

Deal filings since 2016

2025-11-10 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2025-11-10 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
2025-08-01 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2025-08-01 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2025-08-01 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
2025-03-13 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2025-03-13 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2025-03-13 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2024-12-05 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
2024-08-05 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2023-11-15 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2023-09-11 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2023-09-06 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2023-08-23 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2023-08-15 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2023-07-17 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2023-06-16 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2022-12-08 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2022-06-30 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2022-06-22 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2022-03-11 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2021-03-12 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2020-10-13 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2020-04-07 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2020-02-25 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2019-12-09 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2019-11-05 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2018-02-13 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2018-02-13 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
2017-12-26 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2017-08-01 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2017-03-01 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement
2017-01-27 Form 8-K, Item 2.01: Completion of Acquisition or Disposition of Assets
2016-08-24 Form 8-K, Item 1.01: Entry into a Material Definitive Agreement

Read from Keenova Therapeutics’s annual reports (10-K for 2025, 10-K for 2024, 10-K for 2023) and the financial data it files with the SEC, as of 2026-04-15. Every quotation is word for word from the filing linked beside it; how these pages are built and checked. The full record is in its company data sheet.